Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Biogen Inc. Secures Global Rights To Felzartamab Through Greater China Deal With TJ Biopharma
Biogen Inc. has acquired the exclusive worldwide development and commercialization rights to felzartamab by securing TJ Biopharma’s rights in the Greater China Region. This deal, valued at up to $850 million including an upfront payment and potential milestones, expands Biogen’s immunology pipeline and allows it to lead the development, manufacturing, and commercial efforts for the CD38-directed antibody in a key global market. Felzartamab is currently in Phase 3 clinical studies for multiple immune-mediated diseases, including IgA nephropathy and primary membranous nephropathy.